Other languages Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Market Closed - Nasdaq Other stock markets 04:30:00 2024-06-07 pm EDT			5-day change	1st Jan Change
0.1485 ^USD	-4.19%		-26.19%	-89.00%

May. 15	Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 02	Mustang Bio, Inc. announced that it has received $3.3 million in funding	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Mustang Bio Prices Public Offering of 16.9 Million Shares, Accompanying Warrants	Apr. 30
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	Mar. 28
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	Mar. 07
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	Dec. 12
Mustang Bio, Inc. Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	Dec. 11
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Mustang Bio, Inc. Announces Interim Phase 1/2 Data from Mustang's Multicenter Clinical Trial of MB-106	Nov. 02
Mustang Bio to Start Cancer Trial Following FDA Acceptance of IND Application for MB-109; Shares Jump	23-10-26
Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma	23-10-26
Mustang Bio Says Cancer Treatment MB-106 Shows Clinical Response, Committee Approves Increased Dosage	23-08-16
Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy	23-08-16
Mustang Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
UBriGene Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.	23-07-27
Mustang Bio, Inc. Terminates Exclusive License Agreement with Regents of the University of California	23-07-11
Mustang Bio Reports Final Results From Follicular Lymphoma Group of Phase 1/2 Clinical Trial	23-06-15
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy	23-06-15
Mustang Bio to Sell Massachusetts Manufacturing Facility to uBriGene for $11 Million	23-05-18
Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Mustang Bio, Inc.

Equities

MBIO

US62818Q2030

Other languages

Filters